Trade Mark Journal No.2026/015 10 April 2026

UK00004362822 26 March 2026 (5)

LENLOVIQ

International priority date claimed: 18 December 2025 (Ireland) (2025/03236)

Class 5: Pharmaceutical preparations for the treatment of viral infection, fungal infection, HIV infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders and gastrointestinal diseases and disorders; Pharmaceutical preparations for the prevention of HIV infection; Pharmaceutical preparations for the treatment and prevention of HIV infection.

Gilead Sciences Ireland UC

Representative: Aneta Stawska